Cargando…

Impact and Therapeutic Potential of PPARs in Alzheimer's Disease

Peroxisome proliferator activated receptors (PPARs) are well studied for their role of peripheral metabolism, but they also may be involved in the pathogenesis of various disorders of the central nervous system (CNS) including multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's and,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heneka, Michael T, Reyes-Irisarri, Elisabet, Hüll, Michael, Kummer, Markus P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263458/ https://www.ncbi.nlm.nih.gov/pubmed/22654722 http://dx.doi.org/10.2174/157015911798376325

Ejemplares similares

PPARs in Alzheimer's Disease
por: Kummer, Markus P., et al.
Publicado: (2008)

Body Fluid Cytokine Levels in Mild Cognitive Impairment and Alzheimer’s Disease: a Comparative Overview
por: Brosseron, Frederic, et al.
Publicado: (2014)

Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease
por: Chalermpalanupap, Termpanit, et al.
Publicado: (2013)

Peroxisome Proliferator-Activated Receptors (PPARs) as Potential Inducers of Antineoplastic Effects in CNS Tumors
por: Tatenhorst, Lars, et al.
Publicado: (2008)

Pan-PPAR Modulation Effectively Protects APP/PS1 Mice from Amyloid Deposition and Cognitive Deficits
por: Kummer, Markus P., et al.
Publicado: (2014)

Truncated and modified amyloid-beta species
por: Kummer, Markus P, et al.
Publicado: (2014)

Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer’s disease
por: Brosseron, Frederic, et al.
Publicado: (2018)

Microglia in Alzheimer’s disease: Local heroes!
por: Villacampa, Nàdia, et al.
Publicado: (2020)

Therapeutic Advantages of Dual Targeting of PPAR-δ and PPAR-γ in an Experimental Model of Sporadic Alzheimer’s Disease
por: Reich, D, et al.
Publicado: (2018)

PPAR-γ: Therapeutic Potential for Multiple Sclerosis
por: Drew, Paul D., et al.
Publicado: (2008)

Microglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer’s disease pathology
por: Kummer, Markus P, et al.
Publicado: (2021)

PPARδ, a Potential Therapeutic Target for Heart Disease
por: Yang, Qinglin, et al.
Publicado: (2018)

The Contribution of the Locus Coeruleus–Noradrenaline System Degeneration during the Progression of Alzheimer’s Disease
por: Mercan, Dilek, et al.
Publicado: (2022)

NLRP3 is activated in Alzheimer´s disease and contributes to pathology in APP/PS1 mice
por: Heneka, Michael T., et al.
Publicado: (2012)

Therapeutic potential of PPARγ natural agonists in liver diseases
por: Wu, Liwei, et al.
Publicado: (2020)

Therapeutic Potential of PPARγ Activation in Stroke
por: Vemuganti, Raghu
Publicado: (2008)

Potential Therapeutic Effects of PPAR Ligands in Glioblastoma
por: Basilotta, Rossella, et al.
Publicado: (2022)

PPAR Gamma Activators: Off-Target Against Glioma Cell Migration and Brain Invasion
por: Seufert, Sebastian, et al.
Publicado: (2008)

The Nuclear Receptor PPARγ as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease
por: Nicolakakis, Nektaria, et al.
Publicado: (2010)

Selective PPAR-Delta/PPAR-Gamma Activation Improves Cognition in a Model of Alzheimer’s Disease
por: Steinke, Ian, et al.
Publicado: (2023)

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies
por: Pershadsingh, Harrihar A., et al.
Publicado: (2008)

Resveratrol and Neuroprotection: Impact and Its Therapeutic Potential in Alzheimer's Disease
por: Rahman, Md. Habibur, et al.
Publicado: (2020)

PPARα: A potential therapeutic target of cholestasis
por: Ye, Xiaoyin, et al.
Publicado: (2022)

Development of Heterocyclic PPAR Ligands for Potential Therapeutic Applications
por: Virendra, Sharma Arvind, et al.
Publicado: (2022)

Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus
por: Bettcher, Brianne M., et al.
Publicado: (2021)

Therapeutic Implications of PPARγ in Cardiovascular Diseases
por: Hasegawa, Hiroshi, et al.
Publicado: (2010)

Probing Mechanisms and Therapeutic Potential of γ-Secretase in Alzheimer’s Disease
por: Wolfe, Michael S.
Publicado: (2021)

Signaling Mechanisms of Selective PPARγ Modulators in Alzheimer's Disease
por: Govindarajulu, Manoj, et al.
Publicado: (2018)

PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease
por: Corona, Juan Carlos, et al.
Publicado: (2016)

Therapeutic Potential of Phytoconstituents in Management of Alzheimer's Disease
por: Singh, Anurag Kumar, et al.
Publicado: (2021)

Publisher Correction: Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus
por: Bettcher, Brianne M., et al.
Publicado: (2021)

Therapeutic potential of resveratrol in Alzheimer's disease
por: Vingtdeux, Valérie, et al.
Publicado: (2008)

Peptides as Potential Therapeutics for Alzheimer’s Disease
por: Ribarič, Samo
Publicado: (2018)

Distinct modulation of microglial amyloid β phagocytosis and migration by neuropeptides(i)
por: Fleisher-Berkovich, Sigal, et al.
Publicado: (2010)

PPAR agonists as therapeutics for CNS trauma and neurological diseases
por: Mandrekar-Colucci, Shweta, et al.
Publicado: (2013)

Lifestyle and Food Habits Impact on Chronic Diseases: Roles of PPARs
por: d’Angelo, Michele, et al.
Publicado: (2019)

Potential Therapeutic Targets for PPARγ after Spinal Cord Injury
por: McTigue, Dana M.
Publicado: (2008)

PPARδ: A Potential Therapeutic Target for the Treatment of Metabolic Hypertension
por: Jiang, Yanli, et al.
Publicado: (2019)

Therapeutic potential of PPARα agonist in ligature-induced experimental periodontitis
por: Chen, Ying, et al.
Publicado: (2022)

Alzheimer’s Disease and Its Potential Alternative Therapeutics
por: Kisby, Brent, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dmrr30jin2ptp9dib1lsb8s4cr